MX2007004787A - Complejo que comprende mequitazina, una ciclodextrina y un agente de interaccion. - Google Patents

Complejo que comprende mequitazina, una ciclodextrina y un agente de interaccion.

Info

Publication number
MX2007004787A
MX2007004787A MX2007004787A MX2007004787A MX2007004787A MX 2007004787 A MX2007004787 A MX 2007004787A MX 2007004787 A MX2007004787 A MX 2007004787A MX 2007004787 A MX2007004787 A MX 2007004787A MX 2007004787 A MX2007004787 A MX 2007004787A
Authority
MX
Mexico
Prior art keywords
cyclodextrin
mequitazine
complex containing
interaction agent
complex
Prior art date
Application number
MX2007004787A
Other languages
English (en)
Inventor
Bernard Freiss
Lochard Hubert
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2007004787A publication Critical patent/MX2007004787A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invencion se relaciona con un complejo que incluye mequitazina, una ciclodextrina y un agente de interaccion, en el cual la tasa de solubilizacion en agua de la mequitazina complejada, medida en el caso de una mezcla de 2 g/l de mequitazina en agua a 35 degree C despues de 15 minutos de agitacion, es superior a 50% a pH 9; la presente invencion se relaciona asimismo con un procedimiento para la preparacion del complejo antes mencionado y con una composicion farmaceutica que comprende el mismo.
MX2007004787A 2004-10-21 2005-10-19 Complejo que comprende mequitazina, una ciclodextrina y un agente de interaccion. MX2007004787A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0411202A FR2876910B1 (fr) 2004-10-21 2004-10-21 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
PCT/EP2005/055388 WO2006042857A2 (fr) 2004-10-21 2005-10-19 Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction

Publications (1)

Publication Number Publication Date
MX2007004787A true MX2007004787A (es) 2007-05-15

Family

ID=34949969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004787A MX2007004787A (es) 2004-10-21 2005-10-19 Complejo que comprende mequitazina, una ciclodextrina y un agente de interaccion.

Country Status (18)

Country Link
US (1) US7749982B2 (es)
EP (1) EP1802348A2 (es)
JP (1) JP5157447B2 (es)
KR (1) KR101273840B1 (es)
CN (1) CN101043908B (es)
AR (1) AR051593A1 (es)
AU (1) AU2005296875B2 (es)
BR (1) BRPI0516233A (es)
CA (1) CA2583783C (es)
FR (1) FR2876910B1 (es)
IL (1) IL182412A (es)
MX (1) MX2007004787A (es)
NO (1) NO20072433L (es)
NZ (1) NZ555238A (es)
RU (1) RU2389491C2 (es)
TW (1) TWI372759B (es)
WO (1) WO2006042857A2 (es)
ZA (1) ZA200703080B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2914187B1 (fr) * 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.
JP7029886B2 (ja) * 2017-04-28 2022-03-04 ロート製薬株式会社 医薬組成物及びその製造方法
KR20220085094A (ko) 2020-12-14 2022-06-22 메디케어제약 주식회사 알레르기성 결막염을 동반한 만성 비염을 치료하는 약제학적 복합제제

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250534A (es) 1969-03-03 1971-10-20
FR2522660A1 (fr) * 1982-03-05 1983-09-09 Pharmuka Lab Isomere levogyre de la mequitazine, son procede de preparation et medicaments le contenant
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
JP2735122B2 (ja) 1988-06-13 1998-04-02 旭化成工業株式会社 メキタジンの液状シロップ製剤
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
KR920006911B1 (ko) * 1989-06-14 1992-08-22 신풍제약 주식회사 안정한 피록시캄 주사액 조성물 및 그의 제조방법
TW262497B (en) * 1994-06-29 1995-11-11 Toshiba Co Ltd Washing machine
FR2742053B1 (fr) 1995-12-06 1998-03-06 Chauvin Lab Sa Compositions pharmaceutiques a base de mequitazine
WO1998002186A1 (en) * 1996-07-11 1998-01-22 Farmarc Nederland B.V. Inclusion complex containing indole selective serotonin agonist
JPH10167954A (ja) * 1996-12-05 1998-06-23 Takada Seiyaku Kk メキタジン製剤
GB9800936D0 (en) * 1997-05-10 1998-03-11 Univ Nottingham Biofunctional polymers
EP1018340B1 (en) * 1999-01-06 2003-09-10 Tecnimede-Sociedade Tecnico-Medicinal, S.A. Inclusion aminoacid salts compounds of benzimidazole derivatives with cyclodextrins, their preparation and pharmaceutical formulations containing them
FR2788436A1 (fr) * 1999-01-14 2000-07-21 Pf Medicament Composition d'un derive de phenothiazine
FR2815540B1 (fr) * 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
WO2002089851A1 (fr) 2001-03-06 2002-11-14 Separex (Societe Anonyme) Procede de fabrication de complexes hote-client
FR2830761B1 (fr) 2001-10-12 2003-12-12 Pf Medicament Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique
FR2830760B1 (fr) * 2001-10-12 2004-06-04 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique
FR2854079B1 (fr) * 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
ATE504316T1 (de) 2004-04-01 2011-04-15 Pf Medicament Einschlusskomplexe enthaltend piroxicam, ein cyklodextrin und arginin

Also Published As

Publication number Publication date
ZA200703080B (en) 2008-05-28
FR2876910A1 (fr) 2006-04-28
KR101273840B1 (ko) 2013-06-11
WO2006042857A2 (fr) 2006-04-27
TW200621770A (en) 2006-07-01
JP2008517035A (ja) 2008-05-22
JP5157447B2 (ja) 2013-03-06
IL182412A (en) 2015-02-26
FR2876910B1 (fr) 2007-04-13
AU2005296875B2 (en) 2011-03-31
CN101043908A (zh) 2007-09-26
NZ555238A (en) 2010-04-30
AR051593A1 (es) 2007-01-24
CN101043908B (zh) 2011-11-16
KR20070084223A (ko) 2007-08-24
EP1802348A2 (fr) 2007-07-04
NO20072433L (no) 2007-05-11
CA2583783C (fr) 2013-05-21
TWI372759B (en) 2012-09-21
WO2006042857A3 (fr) 2006-07-27
RU2007118640A (ru) 2008-11-27
US7749982B2 (en) 2010-07-06
RU2389491C2 (ru) 2010-05-20
CA2583783A1 (fr) 2006-04-27
AU2005296875A1 (en) 2006-04-27
IL182412A0 (en) 2007-07-24
BRPI0516233A (pt) 2008-08-26
US20070293454A1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
TW200607525A (en) Compositions for delivering highly water soluble drugs
TW200642694A (en) Anti-M-CSF antibody compositions
IL183607A0 (en) Composition for proteasome inhibition
HK1113971A1 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
WO2003027094A3 (en) Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
WO2002085903A3 (en) Amyloid plaque aggregation inhibitors and diagnostic imaging agents
TW200744639A (en) Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
DE602005018043D1 (de) Liposomale formulierungen mit dihydrosphingomyelin und verfahren zu ihrer verwendung
MX2011011857A (es) Formulaciones para el cuidado oral que incrementan la cantidad de zinc soluble.
ATE430559T1 (de) Verfahren zur herstellung von calciumzusammensetzungen im kontinuierlichen fliessbett
WO2006078384A3 (en) Stilbene derivatives and their use
MXPA03004499A (es) Kit de repinotan.
MX2007004787A (es) Complejo que comprende mequitazina, una ciclodextrina y un agente de interaccion.
EP2098225A3 (en) Taste masking system for non-plasticizing drugs
MXPA05008902A (es) Soluciones de drogas en mentol.
HK1093721A1 (en) Ibopamine maleate, method for preparing it and pharmaceutical compositions containing it
BG108945A (en) FIELD OF APPLICATION FOR ANTIGEN-BINDING ACTIVITY OF IMMUNOGLOBULIN PREPARATIONS
TW200621292A (en) Complex comprising piroxicam, a cyclodextrin and arginine
IL176280A0 (en) L-(-)-moprolol l-(+)-tartrate
UA95921C2 (ru) Композиции, которые включают слаборастворимые в воде фармацевтические вещества и противомикробные вещества

Legal Events

Date Code Title Description
FG Grant or registration